Robert F. Kennedy Jr. backs FDA review of popular peptides to determine if compounding pharmacies should be allowed to produce them.
Health Secretary Robert F. Kennedy Jr. is championing a two-day Food and Drug Administration (FDA) meeting to review seven popular peptides, seeking to overturn previous restrictions. While the administration announced the meeting to determine if compounding pharmacies can produce these substances, the review highlights a divide between industry enthusiasm and scientific caution. Peptides are short chains of amino acids that trigger hormones for growth and healing. Supporters, including wellness influencers and Robert F. Kennedy Jr., argue that current restrictions have forced consumers into an unregulated "grey market." However, FDA career scientists expressed concern over the lack of human clinical data, noting that many current claims are based on animal studies. The advisory committee includes several experts with financial ties to the peptide industry, a move that has drawn some criticism. Despite these potential conflicts, the panel will vote on whether to grant pharmacies the green light to compound the substances for conditions such as migraines and ulcerative colitis. The final decision will help shape the "Make America Healthy Again" agenda.